Antileukemic properties of organoplatinum complexes.

The antitumor activity of 46 cis-amineplatinum congeners was evaluated against L1210 leukemia in (C57BL/L X DBA/2)F1 mice. Several compounds in this series significantly prolonged the life-spans of mice with the leukemia. During the selection of the compound that yielded optimal activity [dichloro(1,2-diaminocyclohexane)platinum], the chlorides were substituted with various organic and inorganic anions. The aqueous solubility was greatly increased with retention of significant antileukemic activity. Most of the active compounds were synergistic with cyclophosphamide, and cure rates up to 80% were obtained with certain combinations.

Effects of cis-diamminedichloroplatinum (NSC 119875) on murine and human hemopoietic precursor cells.

The effects of cis-diamminedichloroplatinum (NSC 119875) on murine and human hemopoietic precursor cells were studied in culture. When murine cells from normal and actively regenerating marrows were exposed to cis-diamminedichloroplatinum in culture, washed free of the agent, and assayed for the surviving hemopoietic precursor cells, similar sensitivity curves were obtained. This result indicates the absence of cell-cycle dependency of cis-diaminedichloroplatinum. When marrow cells were exposed to cis-diamminedichloroplatinum in culture at various temperatures, only minimal reduction of cytotoxicity was noted at 4 degrees. This observation, unlike that from the experiment with nitrogen mustard, suggests that the transport of this agent is by passive diffusion. Finally, when the sensitivity of human hemopoietic precursor cells to this agent was assessed using similar conditions and compared to that of murine hemopoietic precursor cells, a significant species difference was observed.

Effects of Dintrato(1,2-diaminocyclohexane)platinum (NSC 239851) On murine myeloma and hemopoietic precursor cells.

We studied the effects of dinitrato (1,2,-diaminocyclohexane)platinum (NSC 239851) on murine myeloma Adj. PC-5 and hemopoietic precursor cells. The median survival time of tumor-bearing mice was significantly affected by i.p. injections of this agent. While 14 mg/kg was a toxic dose, as little as 2 mg/kg prolonged the survival for over 100 days. When cells from normal marrow and actively regenerating marrows were exposed to the agent in culture tubes, washed, and assayed for the surviving hemopoietic precursors, similar sensitivity curves were observed. This result indicates the absence of cell cycle dependency of the agent. When marrow cells were exposed to NSC 239851 at 4 degrees in culture, almost total abrogation of the cytotoxicity was noted. This observation, unlike that from the experiment with the inorganic platinum congener, cis-diamminedichloroplatinum, suggests that the transport of this agents is an active process.

Chemistry and antitumor evaluation of selected classical 2,4-diaminoquinazoline analogues of folic acid.

A series of six 2,4-diaminoquinazoline analogues of folic acid which bear close structural resemblance to methotrexate, 1a, were synthesized by unequivocal routes. Three of these have not been described previously, while complete structural characterization of the remaining compounds is presented for the first time. Each of the compounds was a potent inhibitor of dihydrofolate reductase (DHFR) from rat liver or L1210 leukemia cells having I50 values in a range similar to that of 1a. However, a wide divergence in inhibitory activity toward the growth of human gastrointestinal adenocarcinoma or L1210 leukemia cells in vitro was observed. Compounds having a normal folate configuration at positions 9 and 10 were more inhibitory than their isomeric reversed-bridge counterparts. The N-formyl modifications were the least active of the compounds studied. Unsubstituted or N-methyl modifications competed effectively with tritiated 1a for uptake into L1210 leukemia cells, while N-formyl modifications did not. Against an L1210 cell line resistant to 1a by virtue of altered transport and overproduction of DHFR, partial but not complete cross-resistance was observed for certain analogues. Of the three compounds selected for in vivo evaluation against L1210 leukemia in mice, two had a similar level of antitumor activity to that of 1a. The compound 5,8-dideazamethopterin, 2b, however, was slightly more active than 1a but at substantially reduced dose levels.

Effects of 5,8-dideazaisopteroylglutamate (IAHQ) on L1210 leukemia in mice when given alone and in combination with methotrexate, probenecid, or verapamil.

The folate analogue 5,8-dideazaisopteroylglutamate (IAHQ; NSC-289517) inhibits the growth of a variety of human tumor cells in vitro such as colon, breast and osteosarcoma. Since IAHQ has only modest activity against L1210 leukemia in mice, it was tested in combination with methotrexate (MTX), probenecid, or verapamil in an effort to enhance efficacy. Single drug or drug combinations were administered every other day 3 or 5 times beginning on day 1 following the administration of 10(6) L1210 cells per animal. The combination of IAHQ (100 mg/kg) plus MTX (10 mg/kg) produced a decrease in mean survival time compared to that of MTX alone, regardless of whether the drugs were initiated on the same day or whether either one was started 2 days prior to the other. IAHQ (150 mg/kg) plus verapamil (5, 10, or 20 mg/kg) did not alter significantly the results produced by IAHQ alone. However, the combination of IAHQ (150 mg/kg) plus probenecid (250 mg/kg) augmented the increase in mean survival time above that produced by IAHQ alone by 82% (p = less than 0.001). The results suggest that probenecid could be used to enhance the effectiveness of IAHQ against solid tumors such as colon adenocarcinoma.

meso-2,3-dimercaptosuccinic acid monoalkyl esters: effects on mercury levels in mice.

Seven monoesters of meso-2,3-dimercaptosuccinic acid (DMSA) were evaluated for relative activities in mobilizing and promoting excretion of mercury in mercury-laden mice. Compounds assessed were the ethyl (M-EDMS), n-propyl (Mn-PDMS), isopropyl (Mi-PDMS), n-butyl (Mn-BDMS), isobutyl (Mi-BDMS), n-amyl (Mn-ADMS), and isoamyl (Mi-ADMS) esters. 2,3-Dimercaptopropane-1-sulfonate (DMPS) and DMSA were used as positive controls. After the first oral dose of each compound at 0.5 mmol/kg, DMSA and DMPS reduced the corporal mercury burden 16% and 24%, respectively, compared to controls, while the monoesters effected reductions of 35% (M-EDMS) to 49% (Mi-ADMS). After the second treatment at the same dose, the respective reductions produced by DMSA and DMPS were 24% and 38%, and those conferred by the monoesters ranged from 52% (M-EDMS) to 61% (Mn-BDMS). Determination of the comparative dose-response relationships of DMSA and Mi-ADMS on corporal and renal mercury concentrations revealed the monoester to be more active than DMSA on both parameters at each dose used. The cumulative amount of mercury excreted in urine by control mice over a 3-day period was 7.08 micrograms; this was increased 22%, 85%, and 94% by daily i.p. injections of DMSA, DMPS, and Mi-ADMS, respectively, at a daily dose of 0.1 mmol/kg. The respective cumulative 3-day totals recovered in feces from control mice and from mice treated with DMSA, DMPS, and Mi-ADMS were 9.76, 8.21, 10.44, and 11.73 micrograms. Parallel daily measurements of retained whole body radioactivity from 203Hg in mice were in good agreement with the values calculated from the excretion data.

The rate of the in vivo dithiocarbamate-induced mobilization of hepatic and renal cadmium deposits.

The dithiocarbamate-induced removal of aged cadmium from intracellular sites in the kidneys and liver of mice has been followed as a function of time. The processes are quite rapid with the entire course of the cadmium-removal process being completed in 60-90 min. An examination of the rates at which a dithiocarbamate removes cadmium from hepatic and renal deposits in vivo and from metallothionein in vitro, suggests strongly that the processes are similar. A common mechanism is proposed for both processes which involves the direct attack by the dithiocarbamate on cadmium ion incorporated into metallothionein. Such a mechanism is consistent with the similarities in rates and the degree of overall mobilization of cadmium by the same dithiocarbamate both in vitro and in vivo. The administration of 1 mmol/kg of sodium N-(4-methoxybenzyl)-D-glucamine dithiocarbamate (MeOBDCG) to cadmium-loaded mice leads to a reduction of in vivo renal and hepatic cadmium levels of 45% and 30%, respectively, over a period of only 1 h. Previously the incubation of metallothionein in vitro in the presence of 1 mmol/l of MeOBDCG was found to lead to the reduction of the cadmium content of metallothionein of approximately 60% over a period of 1 h. The administration of higher doses of this compound (2 mmol/kg and 4 mmol/kg) to cadmium-loaded mice led to an even more rapid and more extensive removal of cadmium from both the liver and the kidney. The major factors which limit the ability of dithiocarbamates to mobilize cadmium from in vivo sites appear to be molecular structural features which hinder or prevent the access of the dithiocarbamates to the intracellular sites at which the majority of aged cadmium deposits are held.

Effect of chelate treatments on kidney, bone and brain lead levels of lead-intoxicated mice.

The effects of chelating agent treatment with meso-2,3-dimercaptosuccinic acid (DMSA), Na2CaEDTA, Na2ZnEDTA, and Na3ZnDTPA on the organ lead levels of lead-loaded mice have been determined. At 1 mmol/kg/day i.p., all caused reductions in the lead levels of the kidney after four injections, but only Na2CaEDTA produced a significant reduction in brain lead. All chelating agents caused significant reductions in kidney and brain lead levels when administered at a daily dose of 1 mmol/kg/day for eight days, but only DMSA reduced the bone lead level. In animals given 50 mg Pb/kg or 100 mg Pb/kg, the administration of Na2CaEDTA or DMSA at 1 mmol/kg/day x 8 produced significant reductions in kidney, bone and brain lead levels, but DMSA produced greater reductions of bone lead in both groups and of kidney lead in the group given 100 mg Pb/kg. An examination of published data describing the effect of chelating agent treatment on brain lead levels indicates that DMSA produces a reduction in brain lead levels under all conditions examined to date.

Mobilization of lead in mice by administration of monoalkyl esters of meso-2,3-dimercaptosuccinic acid.

The following six monoalkyl esters of meso-2,3-dimercaptosuccinic acid (DMSA) were synthesized and evaluated for relative activities in mobilizing lead from kidneys and brains of lead-bearing mice: n-propyl (Mn-PDMS), i-propyl (Mi-PDMS), n-butyl (Mn-BDMS), i-butyl (Mi-BDMS), n-amyl (Mn-ADMS) and i-amyl meso-2,3-dimercaptosuccinate (Mi-ADMS). DMSA was used as a positive control. When each was administered intraperitoneally (i.p.) as a single dose of 2.0 mmol/kg, DMSA lowered the kidney lead concentration 52%, while the monoesters effected reductions of 54-75%. Mn-ADMS was toxic at this dose. DMSA lowered the brain lead level 20% when given as a single dose, while the monoesters conferred reductions of 64-87%. When given as 5 daily i.p. injections at 0.5 mmol/kg, DMSA reduced the kidney lead concentration 45%, while the monoesters caused reductions of 56-73%. DMSA lowered the brain lead concentration 35% on the 5-day treatment regimen, while the monoesters evoked reductions of 59-75%. Mi-ADMS was equally effective when given orally or i.p. The i.p. LD50 value of this analog in mice is 3.0 mmol/kg, a value which lies between the reported LD50 doses of DMSA (16.0 mmol/kg) and dimercaprol (1.1 mmol/kg). It is suggested that the ability of these monoesters to cross cell membranes may account for their superiority to DMSA in mobilizing brain lead in this animal model.

Effects of sodium N-methyl-N-dithiocarboxyglucamine on cadmium distribution and excretion.

Sodium N-methyl-N-dithiocarboxyglucamine (MDCG) was evaluated for its efficacy in mobilizing and promoting excretion of metallothionein-bound 109Cd using mice which had received 0.03 mg of CdCl2 . 2 . 5H2O along with 1.0 muCi of 109CdCl2 three weeks earlier. The MDCG-induced change in the fecal excretion of Cd ranged from a 15-fold increase over the control rate at the lowest dose level used (2.2 mmol/kg; 684 mg/kg) up to a 72-fold increase at the highest dose (8.8 mmol/kg; 2736 mg/kg) following three daily injections. The latter treatment regimen resulted in a fecal excretion of almost 30% of the administered Cd over a 3-day period of observation. Urinary Cd excretion was insignificant in both the control and treated groups. The whole body burden of Cd was reduced by over 50% following seven thrice-weekly i.p. injections of MDCG at 8.8 mmol/kg. There was a 60-65% reduction in both the liver and kidney Cd levels following the same treatment regimen. Radioassay of ten other organs and tissues revealed only modest changes. Testicular Cd was decreased slightly at the highest dose level, and heart tissue from each treated group contained slightly more Cd than controls. Results indicated a rather marked specificity of MDCG in lowering the Cd content of two organs most susceptible to Cd-induced toxicity.

Mechanistic aspects of the dithiocarbamate-induced mobilization of cadmium.

The examination of some of the species involved in the in vivo processes in which dithiocarbamates mobilize cadmium from its intracellular deposits indicates that several competing reactions occur. Rates of hydrolytic decomposition of a series of dithiocarbamates capable of mobilizing cadmium in vivo have been determined, and the solubility behavior and nuclear magnetic resonance (NMR) spectra of their cadmium complexes have been examined. Some of the dithiocarbamates most effective in this mobilization process are shown to undergo slow conversion to oxazolidine-2-thiones in the presence of cadmium. All of the cadmium complexes involved in the mobilization process are shown to undergo rapid ligand exchange. While dissociative mechanisms based on the turnover of metallothionein are inconsistent with the experimental data, at least two associative mechanisms are possible. These involve attack on the metallothionein by the dithiocarbamate itself or by a compound derived from it by known metabolic processes.

Selective removal of cadmium from aged hepatic and renal deposits: N-substituted talooctamine dithiocarbamates as cadmium mobilizing agents.

The preparation and examination of three dithiocarbamates derived from N-substituted D-gluco-L-talooctamine reveals that the 4-methoxybenzyl derivative (MeOBGD) is superior to any previously prepared dithiocarbamates as an agent for the mobilization of aged intracellular hepatic cadmium deposits from mice. All of these compounds are also quite effective in reducing whole body burdens of cadmium. The use of these compounds does not result in any increase in the cadmium content of the brain. The selection of these chelating agents for synthesis was suggested by an analysis of the log dose-response curves for the mobilization of renal cadmium by previously studied dithiocarbamates. This revealed that the slope of the percentage renal cadmium mobilized vs the log dosage curve is determined to a considerable extent by the sum of the Hansch pi parameters for the substituents, while the intercept is largely determined by the molecular weight of the compound. The implication of such a correlation is that the ability of a chelating agent to remove cadmium from its aged deposits is determined to some extent by its molecular weight, provided the polarity of the overall molecule is appropriate.

Mobilization of aged in vivo cadmium deposits by diethyl dimercaptosuccinate.

Diethyl dimercaptosuccinate (DEDMS) was prepared and found to be capable of mobilizing cadmium from mice one month after they had been given an injection (i.p.) of 0.03 mg CdCl2.2.5H2O containing 1.0 microCi of 109 CdCl2. When pure, DEDMS is a waxy solid with a melting point of 61-62 degrees C which is soluble in warm peanut oil. Its LD50 value (i.p.) in mice is approximately 2.6 mmol/kg, a value which allows it to be given at a higher dosage than other known lipid-soluble dithiols. This compound is especially effective in reducing hepatic and whole body levels of cadmium; it is not as effective as 2,3-dimercaptopropanol (BAL) in reducing renal cadmium levels.

Dithiocarbamate treatment of chronic cadmium intoxication in mice.

The dithiocarbamate analogs, N-benzyl-N-dithiocarboxy-D-glucamine (BDCG) and N-cyclohexyl-N-(2-hydroxy-3-sulfonatopropyl)dithiocarbamate (CAPSO-DTC), were evaluated as cadmium (Cd) antagonists in mice which had received repetitive injections of Cd to effect accumulation of substantial levels of metallothionein-bound Cd in kidneys and livers. BDCG was highly effective in lowering whole body Cd stores and renal Cd concentrations. While the percent of renal Cd mobilized decreased with increasing Cd concentrations, the total amount of Cd mobilized increased. CAPSO-DTC was also effective in reducing whole body Cd levels, but appeared to have less affinity for renal Cd than did BDCG. Treatment of Cd-laden mice with BDCG provoked only a modest elevation of serum creatinine levels, suggesting that the complex of Cd with BDCG may be less nephrotoxic than the complex of Cd with EDTA or dimercaprol. The log of the percent reduction of renal Cd by BDCG was found to be a linear function of the pretreatment renal Cd concentration, and reductions of whole body Cd burdens correlated closely with reductions of liver and kidney Cd concentrations. It was suggested that a Cd complexing agent of the dithiocarbamate class may have ultimate application in a provocative methodology to estimate body or organ Cd stores based upon the amount of Cd excreted following a standard dose of the chelator.

Schedule dependency of a cadmium-complexing dithiocarbamate analog in mice.

A number of dosing regimens was assessed to determine the optimum schedule of administration of N-(4-methoxybenzyl)-N-dithiocarboxy-D-glucamine (MeOBDCG) in depleting whole-body, renal and hepatic levels of metallothionein-bound cadmium (Cd) in mice. A comparison of 4.0 mmol/kg given as a single injection versus 0.5 mmol/kg given as 8 hourly injections revealed the latter regimen to be superior in reducing renal Cd levels, but less effective than a bolus dose in lowering hepatic Cd concentrations. Administration of 1.33 mmol/kg for 3 consecutive days or 0.8 mmol/kg for 5 days effected a more extensive depletion of renal Cd concentrations than did a single injection of 4.0 mmol/kg. Three injections of 1.0 mmol/kg given at 4- to 7-day intervals were generally more effective in reducing renal Cd concentrations than were 3 consecutive daily injections in mice which had low or moderately high total Cd burdens. The lowest effective dose of MeOBDCG in lowering whole-body, liver and kidney Cd levels when given repetitively was about 0.2 mmol/kg. While schedule variations did not alter appreciably the whole-body Cd reductions at any given total dose of MeOBDCG, repetitive dosing schedules in which injections were given at intervals of several days rather than daily were typically more effective in reducing renal Cd levels. Based upon consideration of pharmacological response as influenced by body surface area, it was calculated that doses of MeOBDCG of the order of 2.0 g/d may be effective in reducing renal Cd levels in individuals with chronic renal dysfunction secondary to chronic Cd intoxication.

Structural influences on intracellular cadmium mobilization by dithiols.

An examination of 5 dithiols, N-(2,3-dimercaptopropyl)phthalamidic acid (DMPA), benzene-1,2-dithiol (BDT), toluene-3,4-dithiol (TDT), alpha, alpha'-dimercapto-o-xylene (DOX), and 4,5-dimethyl-alpha,alpha'-dimercapto-o-xylene (DDOX), reveals that these compounds are all inferior to previously reported compounds as agents for the in vivo mobilization of cadmium from its intracellular sites, although all possess sulfhydryl groups capable of reacting with cadmium. The results demonstrate the considerable importance of those parts of the molecule which do not participate directly in the formation of chelate rings in the determination of the ultimate behavior of such compounds in vivo.

N,N-disubstituted dithiocarbamates as cadmium antagonists: N-(4-methoxybenzyl)-N-dithiocarboxy-D-glucamine.

The newly synthesized dithiocarbamate analog, N-(4-methoxybenzyl)-N-dithiocarboxy-D-glucamine (MeOBDCG) reduced whole-body cadmium levels 66% in cadmium-laden mice when given as 3 injections at 1.0 mmol/kg. Renal and hepatic Cd concentrations were reduced 78 and 85%, respectively. After 6 injections, the whole-body cadmium burden was reduced 71%, while renal and hepatic levels were lowered 84% and 91%, respectively. Mobilized cadmium was excreted almost exclusively by the fecal route. There was no evident toxicity consequent to treatment as judged by mouse body weights and by gross appearance of organs upon dissection. On a molar dose basis, MeOBDCG was more effective than N-benzyl-N-dithiocarboxy-D-glucamine (BDCG) in removing cadmium from both renal and hepatic deposits. An in-vitro assessment of the interaction of MeOBDCG, BDCG and N-methyl-N-dithiocarboxy-D-glucamine with murine cadmium-metallothionein (Cd-MT) revealed a direct relationship between the extent of cadmium depletion from Cd-MT and the relative in-vivo efficacies of the 3 analogs.

Methods of reduction of cisplatin nephrotoxicity.

Cisplatin, an agent widely used in the chemotherapy of a variety of human malignancies, is often dose-limited owing to its nephrotoxicity. Some of the approaches under consideration, regarding the reduction of cisplatin nephrotoxicity, include the use of hydration and osmotic diuresis, pharmacological diuretics, chelating agents or agents which otherwise react with cisplatin or reverse cisplatin-induced deoxyribonucleic acid cross-links, and antioxidants to destroy free radicals, especially superoxide radicals, produced by cisplatin. The effects of each of these and other interventions on cisplatin-induced nephrotoxicity are delineated, along with their proposed mechanisms and effects on therapeutic efficacy. The current status of development of organoplatinum analogs yielding congeners with less nephrotoxicity and greater efficacy is discussed briefly. Finally, a possible role of endogenous and/or exogenous prostaglandins in protecting against or reversing heavy metal nephrotoxicity is suggested.

Diethyldithiocarbamate in treatment of acute cadmium poisoning.

An insoluble complex was synthesized by the reaction of sodium diethyldithiocarbamate trihydrate (DDTC) with CdCl2 X 2.5 H2O (Cd). Elemental analyses of the product yielded a percent composition of each element which was consistent with the postulated structure of two mole equivalents of (DDTC)- and one mole equivalent of Cd++. The DDTC formed a complex with 11 other metal ions tested, but not with Ca++ or Mg++. The complex with Cd was highly insoluble in water, 0.1 N HCl, 0.1 N NaOH, human serum, and carbon tetrachloride, but it was soluble in pure dimethyl sulfoxide. The DDTC protected mice from a greater than LD100 dose of Cd. This protective effect was more pronounced when DDTC treatment was delayed at least 30 min after i.p. administration of Cd. More than 98 percent of mice treated with 500 mg per kg of DDTC 30 min to five hrs after Cd administration survived, and 50 percent survived when treatment wad delayed for eight hrs. Administration of DDTC prior to or immediately after Cd gave less protection. The lowest (DDTC)-/Cd++ molar dose ratio which resulted in 100 percent survival following the otherwise lethal dose of Cd was 7.6, which was less than four times the theoretical stoichiometric molar ratio for formation of the complex. The LD50 of the complex in mice wa approximately 650 mg per kg of the i.p. route, indicative of a low degree of dissociation in vivo.

Effects of diethyldithiocarbamate on organ distribution and excretion of cadmium.

Sodium diethyldithiocarbamate (DDTC) was evaluated for its efficacy in promoting organ mobilization and excretion of metallothionein-bound cadmium (Cd) using mice which received a single injection of CdCl2 X 2.5 H2O, 0.03 mg per mouse, along with 109CdCl2 three to six weeks earlier. After seven or 13 i.p. injections of DDTC, 500 mg per kg, over a two or four week interval, DDTC was highly effective in mobilizing Cd from kidney (Ki) and spleen (Sp), but less effective in removing it from liver (Li). Treatment with DDTC moderately enhanced Cd levels in lung (Lu), heart (He) and testes (Te), and increased brain (Br) levels to over 500 percent of control values. Relative accumulation of Cd in organs of control mice were in the order Li greater than Ki greater than Sp greater than Lu greater than He greater than Te greater than Br. The extreme values were Li = 57 percent and Br = 0.07 percent of the Cd administered. Even though a major portion of Cd mobilized was from the kidneys, excretion was apparently exclusively by the fecal route.